The Food and Drug Administration (FDA) announced it will hold a panel review this summer to consider easing restrictions on over six peptide injections, many of which are popular among wellness influencers and celebrities. These peptides, including BPC-157, are marketed for healing injuries, reducing inflammation, and anti-aging benefits, but most lack comprehensive safety research or FDA approval.

This move follows longstanding promises by Health Secretary Robert F. Kennedy Jr. to relax regulations on peptides. Kennedy has publicly expressed his support, claiming personal benefits from their use, and has discussed using peptides for his injuries. The FDA’s upcoming meeting will evaluate whether these substances should be added to a list allowing pharmacies to produce them more freely, potentially removing them from a high-risk category. Critics warn that this could undermine the FDA’s drug safety protocols, as many peptides have been linked to significant health risks such as cancer and organ damage.

The decision has raised concerns among medical experts and former FDA officials, who argue that allowing easier access without rigorous testing poses a profound public health threat. The current regulatory environment restricts many unapproved peptides, but with vacancies on the FDA’s pharmacy panel, there’s speculation that Kennedy’s influence might sway the outcome. Meanwhile, the popularity of peptides continues to grow, fueled by online marketing and celebrity endorsements, despite limited scientific validation of their safety and efficacy.